JDRF and Becton, Dickinson and Company (BD) are accelerating the development of new products that combine BD's insulin infusion and glucose sensing technologies through a new three-year collaboration. This commitment is an extension of ...
The FDA has granted orphan drug designation for Andromeda Biotech's DiaPep277 to treat type 1 diabetes (T1D) patients with residual beta cell function. The orphan drug status offers seven years marketing exclusivity from the time of ...
Tags: DiaPep277, type 1 diabetes, T1D, residual beta cell